The biological basis for the use of an anti-androgen and a 5-α-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review

Oncology Reports

Volumn 11, Issue 6, 2004, Pages 1325-1329

  Wang, Long G ^a   Mencher, Simon K ^a   McCarron, J P ^b   Ferrari, Anna C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

5 reductase inhibitor; Anti androgen; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; ENZYME INHIBITOR; FINASTERIDE; STEROID 5ALPHA REDUCTASE;

AGED; ARTICLE; CASE REPORT; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; HUMAN; MALE; METABOLISM; NEOPLASM; PHOSPHORYLATION; PROSTATE TUMOR; TUMOR RECURRENCE;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; DRUG SYNERGISM; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE 5-ALPHA-REDUCTASE; TUMOR CELLS, CULTURED;

EID: 12344322290     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.6.1325     Document Type: Article

References (30)

1. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A and Blackledge G: A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33: 447-456, 1998. (Pubitemid 28251992)
2. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Gotting-Smith K and Blackledge GR: Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 51: 389-396,1998. (Pubitemid 28136673)
3. Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K and Cockshott ID: Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. Eur Urol 33: 39-53, 1998. (Pubitemid 28033416)
4. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ and Kolvenbag GJ: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 50: 330-336, 1997. (Pubitemid 27428107)
5. Tyrrell CJ: Controversies in the management of advanced prostate cancer. Br J Cancer 79: 146-155, 1999.
6. Wirth M, Tyrrell C, Wallace M, Delaere KP, Sanchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes CF, Borchers TM, Morris T and Stone A: Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 58: 146-151, 2001.
7. Abrahamsson PA: Treatment of locally advanced prostate cancer - a new role for antiandrogen monotherapy? Eur Urol 39 (Suppl. 1): 22-28, 2001.
8. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, van Poppel H, Tammela TL, Chamberlain M, Carroll K and Melezinek I: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 164: 1579-1582, 2000.
9. Fleshner NE and Trachtenberg J: Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 154: 1642-1646, 1995.
10. Kirby R, Robertson C, Turkes A, Griffiths K, Denis LJ, Boyle P, Altwein J and Schroder F: Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Prostate 40: 105-114, 1999. (Pubitemid 29304701)
11. Ornstein DK, Rao GS, Johnson B, Charlton ET and Andriole GL: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 48: 901-905, 1996. (Pubitemid 26427098)
12. Bartsch G, Rittmaster RS and Klocker H: Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 37: 367-380, 2000. (Pubitemid 30157796)
13. Steiner JF: Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 30: 16-27, 1996.
14. Steers WD: 5alpha-reductase activity in the prostate. Urology 58: 17-24, 2001.
15. Rittmaster RS: Finasteride. N Engl J Med 330: 120-125, 1994.
16. Gleave ME, Bruchovsky N, Moore MJ and Venner P: Prostate cancer: 9. treatment of advanced disease. Can Med Assoc J 160: 225-232, 1999. (Pubitemid 29060375)
17. Hickson RC, Ball KL and Falduto MT: Adverse effects of anabolic steroids. Med Toxicol Adverse Drug Exp 4: 254-271, 1989. (Pubitemid 19202529)
18. Brawley OW and Parnes H: Prostate cancer prevention trials in the USA. Eur J Cancer 36: 1312-1315, 2000.
19. Cote RJ, Skinner EC, Salem CE, Mertes SJ, Stanczyk FZ, Henderson BE, Pike MC and Ross RK: The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer 78: 413-418, 1998. (Pubitemid 28336432)
20. Comstock GW, Gordon GB and Hsing AW: The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev 2: 219-221, 1993.
21. Dorgan JF, Albanes D, Virtamo J, Heinonen OP, Chandler DW, Galmarini M, McShane LM, Barrett MJ, Tangrea J and Taylor PR: Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev 7: 1069-1074, 1998. (Pubitemid 29001661)
22. Gann PH, Hennekens CH, Ma J, Longcope C and Stampfer MJ: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88: 1118-1126, 1996. (Pubitemid 26274606)
23. Hsing AW and Comstock GW: Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 2: 27-32, 1993.
24. Nomura A, Heilbrun LK, Stemmermann GN and Judd HL: Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 48: 3515-3517, 1988.
25. Buchanan G, Irvine RA, Coetzee GA and Tilley WD: Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 20: 207-223, 2001. (Pubitemid 34595269)
26. Montgomery JS, Price DK and Figg WD: The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol 195: 138-146, 2001. (Pubitemid 32899021)
27. Wang LG, Liu XM, Kreis W and Budman DR: Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Biochem Biophys Res Commun 259: 21-28, 1999. (Pubitemid 29263987)
28. Wang LG, Liu XM, Kreis W and Budman DR: Downregulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 57: 714-719, 1997. (Pubitemid 27085656)
29. Wang LG, Liu XM, Budman DR and Kreis W: Synergistic effect of estramustine and [3′-keto-Bmt1]-[Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells. Biochem Pharmacol 58: 1115-1121, 1999. (Pubitemid 29381512)
30. Chou JCT: Dose-effect analysis with microcomputers: quantitation of ED50, LD50, synergism, antagonism, low dose risk, receptor-ligand binding and enzyme kinetics. Eur J Biochem. Manual and Software, Biosoft, Cambridge, UK, 1987.